A Study to Assess Mitomic Prostate Test for Prostate Cancer Screening

NCT05180305 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-01-06

No results posted yet for this study

Summary

To evaluate the diagnostic accuracy of the Mitomic Prostate Test (MPT) comparing to prostate biopsy within the intended use population.

Conditions

Interventions

DIAGNOSTIC_TEST

Mitomic Prostate Test

Mitomic Prostate Test

Sponsors & Collaborators

  • TSH Biopharm Corporation Limited

    lead INDUSTRY

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-27
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05180305 on ClinicalTrials.gov